Sec. 107. GAO study
152 words·~1 min read·
/bill/113/hr/3204/eh/section-107·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
Not later than 36 months after the date of the enactment of this Act, the Comptroller General of the United States shall submit to Congress a report on pharmacy compounding and the adequacy of State and Federal efforts to assure the safety of compounded drugs. The report required under this section shall include— a review of pharmacy compounding in each State, and the settings in which such compounding occurs; a review of the State laws and policies governing pharmacy compounding, including enforcement of State laws and policies; an assessment of the available tools to permit purchasers of compounded drugs to determine the safety and quality of such drugs; an evaluation of the effectiveness of the communication among States and between States and the Food and Drug Administration regarding compounding; and an evaluation of the Food and Drug Administration's implementation of sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.